Breakpoints in antibiotic sensitivity testing and their clinical relevance

Journal of Chemotherapy

Volumn 9, Issue SUPPL. 1, 1997, Pages 47-54

  Hamilton Miller, J M T ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Brekpoints; Disc diffusion; MIC; Sensitivity testing

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFALOTIN; CEFAMANDOLE; CEFAPIRIN; CEFEPIME; CEFPIROME; CEFRADINE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; MACROLIDE; METICILLIN; NALIDIXIC ACID; NITROFURANTOIN; PENICILLIN DERIVATIVE; PENICILLIN G; RIFAMPICIN; SULFAMETHOXAZOLE; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM; CONFERENCE PAPER; FUNGUS; HUMAN; INFECTION; MINIMUM INHIBITORY CONCENTRATION; TECHNIQUE;

HUMANS; MICROBIAL SENSITIVITY TESTS; PREDICTIVE VALUE OF TESTS;

EID: 0030787836     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Fleming A. On the antibacterial action of cultures of Penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 1929; 10: 226-229.
2. Heatley NG. Method for assay of penicillin. Biochem J 1944; 38: 61-65.
3. Kronvall G, Ringertz S. Antibiotic disk diffusion testing revisited. Single strain regression analysis. APMIS 1991; 99: 295-306.
4. NCCLS. Development of in vitro susceptibility testing criteria and quality control parameters. Document M23-T. National Committee for Clinical Laboratory Standards, Villanova PA, 1990.
5. Ericsson HM, Sherris JC. Antibiotic sensitivity testing: report of an international collaborative study. Act Pathol Microbiol Scand B 1971; suppl 217: 1-90.
6. Report of Working Party. A guide to sensitivity testing. J Antimicrob Chemother 1991; 27 (Suppl D): 1-80.
7. Stokes EJ, Ridgway GL. Antibiotic sensitivity tests. In: Clinical Microbiology (6th ed) London, Edward Arnold 1987: 204-221.
8. Brown DFJ. The comparative methods of antimicrobial susceptibility testing - time for a change? J Antimicrob Chemother 1990; 25: 307-310.
9. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 1986; 75: 1028-1040.
10. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966; 45: 493-496.
11. NCCLS. Performance standards for antimicrobial susceptibility testing. Document M100-S6. National Committee for Clinical Laboratory Standards, Wayne, PA. 1995.
12. Petersdorf RG, Plorde JJ. The usefulness of in vitro sensitivity tests in antibiotic therapy. Annu Rev Med 1963; 14: 41-56.
13. Second Report of the Expert Committee on Antibiotics. Standardization of methods for conducting microbic sensitivity tests. Tech Rep Ser Wld Hlth Org 1961; 210: 1-24.
14. Soussy CJ, Cluzel R, Courvalin P and the Comite de l'Antibiogramme de la Societe Francaise de Microbiologie. Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria in France. Eur J Clin Microbiol Inf Dis 1994; 13: 238-246.
15. Van Klingeren B, Mouton RP (eds). Standardization of susceptibility testing. Bilthoven, Dutch Working Party; 1990.
16. Hamilton-Miller JMT. Protein binding of antibiotics: does it matter? In: Serious Infections - Treatment and Prevention. London: Update Publications, 1985: 42-52.
17. Mouton JWL, Vinks AATMM. Is continuous infusion of β-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicr Chemother 1996; 38: 5-15.
18. Munckhof WJ, Grayson ML, Turnidge JD. A metaanalysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37: 645-663.
19. Lorian V, Gemmell C. Effect of low antibiotic concentrations on bacteria: effects on ultrastructure, virulence, and susceptibility to immunodefences. IN: Lorian V (ed) Antibiotics in Laboratory Medicine 3rd ed. Baltimore: Williams & Wilkins, 1991; 493-555.
20. Ritts RL. Antibiotics as biological response modifiers. J Antimicrob Chemother 1990; 26 (suppl C): 31-36.
21. Van Vlem B, Vanholder R, De Paepe P, Vogelaers D, Ringoir S. Immunomodulating effects of antibiotics: literature review. Infection 1996; 24: 275-291.
22. Ringertz S, Olsson-Liljequist B, Kronvall G, Antimicrobial susceptibility testing of Haemophilus influenzae. Improvement of accuracy of the disc diffusion test. J Antimicrob Chemother 1990; 26: 479-489.
23. Manninen R, Eerola E, Huovinen P. Disk diffusion susceptibility tests: need for laboratory-specific breakpoints. Scand J Infect Dis 1995; 27: 45-49.
24. Metzler CM, DeHaan RM. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis 1974; 130: 588-594.
25. Hamilton-Miller JMT. Definition ot breakpoint for sensitivity to trimethoprim in Gram-positive cocci: use of Chauvenet's criterion. Microbios Lett 1987; 36: 65-69.
26. Hamilton-Miller JMT. Use of laboratory tests in predicting the therapeutic efficacy of antimicrobial compounds. In: Brumfitt W, Hamilton-Miller JMT ed. New Perspectives in Clinical Microbiology. London: Kluwer Medical, 1978; 31-43.
27. McCabe WR, Jackson GG. Gram-negative bacteremia. II. Clinical, laboratory, and therapeutic observations. Arch Int Med 1962; 110: 856-864.
28. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Int Med 1985; 145: 1621-1629.
29. Barnes MP. Influence ot laboratory reports on prescribing of antimicrobials for urinary tract infection. J Clin Path 1980; 33: 481-483.
30. Sturm AW. The laboratory and antibiotic prescribing. J Antimicrob Chemother 1985; 15: 255-256.
31. Bell S. The relevance of bacteriology tests to the clinical use of antibiotics in domiciliary practice. J Antimicrob Chemother 1976; 2: 110-111.
32. Greenwood D. Antimicrobial susceptibility testing: are we wasting our time? Br J Biomed Sci 1993; 50: 31-34.
33. Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol 1987; 6: 1-11.
34. Brumfitt W, Hamilton-Miller JMT. Principles and practice of antimicrobial chemotherapy. In: A very CSS, ed, Drug Treatment, 3rd edition. New Zealand, ADIS Press; 1987: 1207-1235.
35. Shah PM, Schafer V, Zieman M, Krauskopf S and Microbiological and Clinical Study Groups. Comparison of clinical response to cefpirome treatment and minimum inhibitory concentration of causative isolates. J Antimicrob Chemother 1992; 29 (suppl A): 75-80.
36. Thornsberry C. Cefaclor AF: correlation ot microbiology and clinical outcome. Postgrad Med J 1992; 68 (suppl 3): S10-S16.
37. European Study Group on Antibiotic Breakpoints. Breakpoint determination; cetepime. Eur J Clin Microbiol Infect Dis 1994; 13: 282-283.
38. Davey PG. Relationship between serum concentrations of antibacterial drugs and the outcome of bacterial infections. Res Clin Forums 1990; 12 (no 4): 35-43.
39. Eudy WW. Correlations between in vitro sensitivity testing and therapeutic response in urinary tract infections. Urology 1973; 2: 519-524.
40. Stamey TA, Fair WR, Timothy MM, Millar MA, Mihara G, Lowery YC. Serum versus urinary antimicrobial concentrations in cure of urinary tract infections. N Eng J Med 1974; 291: 1159-1163.
41. Jackson GG. Methods for the clinical evaluation of antibiotics in urinary tract infections. Scand J Infect Dis 1978; suppl 14: 289-294.
42. Naber KG. Urinary antibiotic levels and their clinical relevance. Res Clin Forum 1990; 12 (no 4): 45-52.
43. Hamilton-Miller JMT. Antibiotic treatment of enterococcal infection. Antimicrob Agents Chemother 1989; 33: 2164.
44. Greenwood D. Fixed or variable concentrations of ß-lactamase inhibitors in in-vitro tests? J Antimicrob Chemother 1996; 38: 17-20.
45. Brumfitt W, Hamilton-Miller JMT. Combinations of sulphonamides with diaminopyrimidines: how, when and why? J Chemother 1995; 7: 136-139.
46. Barry AL, Jones RN, Thornsberry C. Reliability of cefaclor, cetazolin, cefamandole and cephalothin disks to predict susceptibility of Enterobacteriaceae, Staphylococcus species and Haemophilus influenzae. Am J Clin Pathol 1985; 84: 643-648.
47. Brumfitt W, Hamilton-Miller JMT, Cooper J. Clinical, pharmacokinetic and laboratory experience with cephradine. Proceedings 10th International Congress of Chemotherapy (Zurich, 1977), vol 2; Washington, American Society for Microbiology, 1978; 865-867.
48. Hamilton-Miller JMT, Iravani A, Brumfitt W, Byers KS, Dere WH. Comparative trials of cefaclor AF in uncomplicated cystitis and asymptomatic bacteriuria. Postgrad Med J 1992; 68 (suppl 3): S60-S66.
49. Cormican MG, Pfaller MA. Standardization of antifungal susceptibility testing. J Antimicrob Chemother 1996; 38: 561-578.
50. Odds FC. Resistance of clinically important yeasts to antifungal agents. Int J Antimicrob Agents 1996; 6: 145-147.